By Health In Five Writer
“HMD’s top priority right now is to help the government to combat the pandemic. It had been ensuring continuity of the supply chain and its manufacturing plants to ensure no shortages in India for its critically needed disposable devices during the COVID-19 crisis,” Rajiv Nath, Managing Director, HMD said in a statement.
The company said that it has ‘made India proud’ with its global recognition as a ‘key international supplier’ of critically needed syringes to the COVAX facility of WHO (via UNICEF), Brazil and even Japan for COVID vaccination.
Last year in December, HMD had dispatched 14 crore AD syringes to the COVAX stockpile facility created in anticipation of supporting the global worldwide vaccination drive.
“This is in addition to our ongoing global contractual commitments to support global vaccination projects for 0.1ml and 0.5 ml AD Kojak syringes in developing world whether for yellow fever or measles or Hepatitis B or pentavalent or BCG etc. in addition to Covid vaccination requirements of 0.3ml AD syringes for Pfizer’s vaccines,” Nath said.
He added that company focus is India and its needs, so they have reserved over two-thirds capacity for the domestic need and continue to decline orders from many overseas new potential buyers.
“From 50 crore pieces per annum capacity of 0.5 ml AD syringes in June 2020, we have increased production rate to 80 crore per annum in May 2021 and currently achieved target capacity of producing 100 crore AD syringes. Hopefully 125 crore pieces per annum by March 2022, for this one size alone,”Nath informed.
Further highlighted that over 440 million syringes will be supplied by HMD for India’s massive vaccination drive by September of which 365 million were supplied till July this year alongside supplies of Dispovan to the private hospitals and vaccination clinics.